Adaptimmune Nabs Breakthrough Therapy Designation for NY-ESO T-Cell Therapy

Adaptimmune Therapeutics has scooped up FDA breakthrough therapy designation for its enhanced T-cell therapy targeting NY-ESO in synovial sarcoma for HLA-A*201, HLA-A*205 or HLA-A*206 allele-positive patients.

In a Phase 1/2 trial, 60 percent of patients receiving the target dose of cells responded, while 50 percent receiving any dose of cells responded. Additionally, 90 percent of subjects receiving the target dose and 75 percent of all patients were alive and on long-term follow-up.

The company will aim to launch pivotal studies of the therapy by the end of the year.